Business Segments · Operating Earnings
Established Pharmaceuticals — Operating Earnings
Abbott Established Pharmaceuticals — Operating Earnings increased by 43.1% to $365.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.5%, from $298.00M to $365.00M. Over 4 years (FY 2021 to FY 2025), Established Pharmaceuticals — Operating Earnings shows an upward trend with a 9.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026
Rolls up toOperating Income
How to read this metric
An increase indicates improved profitability through higher sales or better cost control.
Detailed definition
This metric represents the profit generated by the established pharmaceuticals segment after deducting all operating exp...
Peer comparison
Comparable to 'Segment Operating Income' or 'EBIT' for business units at other healthcare companies.
Metric ID:
abt_segment_established_pharmaceuticals_operating_earningsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 220M | 293M | 207M | 242M | 258M | 331M | 218M | 300M | 307M | 345M | 254M | 267M | 315M | 380M | 271M | 298M | 346M | 391M | 255M | 365M |
| QoQ Change | — | +33.2% | -29.4% | +16.9% | +6.6% | +28.3% | -34.1% | +37.6% | +2.3% | +12.4% | -26.4% | +5.1% | +18.0% | +20.6% | -28.7% | +10.0% | +16.1% | +13.0% | -34.8% | +43.1% |
| YoY Change | — | — | — | — | +17.3% | +13.0% | +5.3% | +24.0% | +19.0% | +4.2% | +16.5% | -11.0% | +2.6% | +10.1% | +6.7% | +11.6% | +9.8% | +2.9% | -5.9% | +22.5% |
Range207M – 391M
CAGR+11.2%
Avg YoY Growth+9.3%
Median YoY Growth+10.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Abbott's established pharmaceuticals — operating earnings?
- Abbott (ABT) reported established pharmaceuticals — operating earnings of $365.00M in Q1 2026.
- How has Abbott's established pharmaceuticals — operating earnings changed year-over-year?
- Abbott's established pharmaceuticals — operating earnings increased by 22.5% year-over-year, from $298.00M to $365.00M.
- What is the long-term trend for Abbott's established pharmaceuticals — operating earnings?
- Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — operating earnings has grown at a 9.8% compound annual growth rate (CAGR), from $889.00M to $1.29B.
- What does established pharmaceuticals — operating earnings mean?
- The profit earned from segment operations after all operating expenses are paid.